De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Medicenna Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Fahar Merchant

Algemeen directeur

CA$1.0m

Totale compensatie

Percentage CEO-salaris	50.3%
Dienstverband CEO	13yrs
Eigendom CEO	7.5%
Management gemiddelde ambtstermijn	10.1yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Analyse CEO-vergoeding

Hoe is Fahar Merchant's beloning veranderd ten opzichte van Medicenna Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$26m
Mar 31 2024	CA$1m	CA$519k	-CA$25m
Dec 31 2023	n/a	n/a	-CA$15m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$9m
Mar 31 2023	CA$877k	CA$428k	-CA$10m
Dec 31 2022	n/a	n/a	-CA$9m
Sep 30 2022	n/a	n/a	-CA$13m
Jun 30 2022	n/a	n/a	-CA$20m
Mar 31 2022	CA$894k	CA$436k	-CA$23m
Dec 31 2021	n/a	n/a	-CA$25m
Sep 30 2021	n/a	n/a	-CA$26m
Jun 30 2021	n/a	n/a	-CA$21m
Mar 31 2021	CA$868k	CA$543k	-CA$17m
Dec 31 2020	n/a	n/a	-CA$14m
Sep 30 2020	n/a	n/a	-CA$11m
Jun 30 2020	n/a	n/a	-CA$9m
Mar 31 2020	CA$852k	CA$411k	-CA$8m
Dec 31 2019	n/a	n/a	-CA$7m
Sep 30 2019	n/a	n/a	-CA$6m
Jun 30 2019	n/a	n/a	-CA$5m
Mar 31 2019	CA$565k	CA$375k	-CA$5m
Dec 31 2018	n/a	n/a	-CA$5m
Sep 30 2018	n/a	n/a	-CA$5m
Jun 30 2018	n/a	n/a	-CA$6m
Mar 31 2018	CA$907k	CA$380k	-CA$7m

Compensatie versus markt: De totale vergoeding ($USD 764.11K ) Fahar } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 176.73K ).

Compensatie versus inkomsten: De vergoeding van Fahar is gestegen terwijl het bedrijf verliesgevend is.

CEO

Fahar Merchant (67 yo)

13yrs

Tenure

CA$1,030,905

Compensatie

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Fahar Merchant	Founder	13yrs	CA$1.03m	7.49% CA$ 11.8m
Rosemina Merchant	Founder & Chief Development Officer	13.5yrs	CA$705.93k	7.27% CA$ 11.5m
David Hyman	Chief Financial Officer	less than a year	CA$165.09k	0.026% CA$ 41.0k
Samuel Denmeade	Scientific Advisor	no data	geen gegevens	geen gegevens

10.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MDNA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Fahar Merchant	Founder	13yrs	CA$1.03m	7.49% CA$ 11.8m
John Geltosky	Independent Director	4.1yrs	CA$96.70k	geen gegevens
Karen Dawes	Independent Director	5.1yrs	CA$96.70k	0.032% CA$ 51.3k
Albert Beraldo	Lead Independent Director	7.9yrs	CA$129.20k	0.42% CA$ 666.3k
Lillian Siu	Member of Clinical Advisory Board	2.6yrs	geen gegevens	geen gegevens
David Mooney	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
John Sampson	Independent Director	3.1yrs	CA$86.70k	geen gegevens
Sergio Quezada	Chairman of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Paolo Ascierto	Member of Clinical Advisory Board	2.6yrs	geen gegevens	geen gegevens
Burkhard Becher	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
William Redmond	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Hussein Tawbi	Member of Clinical Advisory Board	2.6yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MDNA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Medicenna Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Recent updates

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Medicenna Therapeutics Corp. Announces Board Appointments

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada

Founder recently bought CA$106k worth of stock

Medicenna Therapeutics Corp. Doses First Patient in MDNA11 Phase 1/2 Ability Study

Consensus revenue estimates fall to CA$125.0k

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely